Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Sanofi, DBV Technologies partner to produce Viaskin's Active Pharmaceutical Ingredients

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergies, announced today that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin's Active Pharmaceutical Ingredients (API), such as the peanut protein extract.

5 Mar 2013

Eisai, DSM sign 3 year master supply agreement for production of sterile products

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.

5 Mar 2013

UT Arlington receives new $7.5 million gift from Shimadzu Scientific Instruments

A new $7.5 million gift from Shimadzu Scientific Instruments to The University of Texas at Arlington will support one of the most significant installments of advanced scientific equipment in the United States, propelling the University to new heights of discovery and innovation.

1 Mar 2013

Medical Adhesives for Reusable or Disposable Medical Devices

An interview with Robert Michaels, discussing the major challenges faced by engineers designing medical devices and the development of new medical adhesives.

From Master Bond Inc. 28 Feb 2013

Wyss Founding Director receives NC3Rs 3Rs Prize for Lung-on-a-Chip

In a London ceremony today, Wyss Founding Director Don Ingber, M.D., Ph.D., received the NC3Rs 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) for his innovative Lung-on-a-Chip -- a microdevice lined by human cells that recapitulates complex functions of the living lung.

28 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

New handheld ultrasound device available from Signostics

Physicians now have access to an even faster and more accurate handheld ultrasound device, with Signostics today unveiling its new “Signos RT” model.

26 Feb 2013

Pharmaceutical research centre led by the University of Limerick to receive investment from Science Foundation Ireland

A research centre led by the University of Limerick dedicated to supporting the pharmaceutical industry in Ireland will benefit from today’s announcement of €300 million investment by Science Foundation Ireland. The Irish pharmaceutical industry supports over 60,000 Irish jobs and exports over €50 billion annually.

26 Feb 2013

Sius single-use tangential flow filtration skid from Novasep

Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the launch of its Sius single-use tangential flow filtration (TFF) skid.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

Glide Pharma announces completion of $21.4 million investment round

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.

26 Feb 2013

Comprehensive portfolio of antiretroviral products from Mylan

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products.

25 Feb 2013

EnvisionTEC launches 3Dent for manufacture of dental models

EnvisionTEC, a leading manufacturer and distributor of patented 3D rapid prototyping and manufacturing solutions, unveiled the newest addition to its dental lineup, 3Dent, specifically for the manufacture of dental models.

23 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

IntegraGen, Lab21 collaborate to develop new microRNA assay for colorectal cancer

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

22 Feb 2013

Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics

Breast cancer is a major concern throughout the world. It is the number 1 cancer among women and in the Western world it generates approximately one new case per minute: 24 hours a day 7 days a week.

22 Feb 2013

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo Pharmaceuticals, Inc. announced that RESCULA Eye Drops had been launched in the U.S. market.

21 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

Oncolytics Biotech to commence underwritten public offering of common shares

Oncolytics Biotech Inc. announced today its intention, subject to market and other conditions, to commence an underwritten public offering of common shares. The number of common shares to be distributed and the price of each common share will be determined in the context of the market with final terms to be determined at the time of pricing.

19 Feb 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013